Mumbai: A newly identified COVID-19 variant, PJ.2.1, is spreading across several countries after its first detection in Ontario, Canada, on May 2, 2026, prompting renewed attention from researchers and public health authorities.
The variant has since been reported in the United States, Europe, Australia, New Zealand and parts of Asia. Research published in the Journal of Infection in October 2026 suggests that changes in its spike protein may help it bind more effectively to human cells, potentially contributing to its spread.
Genomic surveillance data from Public Health Ontario showed that PJ.2.1 accounted for 25.2% of sequenced samples between September 20 and October 17, compared with 16.9% in the preceding four weeks.
Scientists have identified increased interaction with the ACE2 receptor as a possible factor behind its growth. However, laboratory findings indicate that antibodies generated by the LP.8.1-adapted vaccine can still neutralise the variant, with only a 1.8-fold reduction in neutralisation compared with the reference strain.
There is currently no evidence establishing that PJ.2.1 causes more severe illness or increases hospitalisation and death rates.
The variant also has no confirmed symptoms distinct from other COVID-19 strains. Common signs include fever, cough, sore throat, runny nose, headache, body aches and fatigue. Some patients may experience breathing difficulties or changes in smell and taste.
Older adults, people with weakened immunity and those with underlying medical conditions remain particularly vulnerable to severe complications. Health experts recommend appropriate vaccination, testing and continued genomic surveillance.
For India, INSACOG remains responsible for monitoring circulating coronavirus lineages. However, available information does not confirm whether PJ.2.1 has been detected in the country. The World Health Organization’s July 2026 update also did not list the lineage among its monitored variants.
